C-Reactive Protein is a Strong Independent Predictor of Death in Type 2 Diabetes: Association with Multiple Facets of the Metabolic Syndrome

Abstract

Introduction: It has been suggested that atherosclerotic vascular disease is a chronic inflammatory process. The aim of this study was to investigate the importance of C-reactive protein (CRP) as a cardiovascular risk marker and predictor of death, as well as its relation to other factors of the metabolic syndrome in a cohort of type 2 diabetic patients at high risk of severe macrovascular complications. Material and Methods: 592 patients, aged 55 to 74 years (311 men, 281 women), with signs and symptoms of circulation deficits were examined by duplex ultrasound for suspected cerebrovascular and peripheral arterial disease and followed over a period of 5 years. At baseline, 292 patients of the total group had type 2 diabetes (49.3 %). Ischemic heart disease was present in 40.2 %, internal carotid stenosis in 21.9 % and peripheral arterial disease in 39.7 % of the subjects. Results: During the observation period, 104 patients had died, 72 (69.2 %) due to cardiovascular causes. Non-fatal myocardial infarction occurred in 39 patients (7.4 %), non-fatal stroke in 70 patients (13.3 %) and amputations because of gangrene were unavoidable in 24 patients (4.6 %). In Cox regression analysis, CRP was the strongest predictor of death and cardiovascular death in the total cohort (RR 3.7 [95 % CI 1.86 - 7.50] and 5.4 [2.13 - 13.76]), as well as in the type 2 diabetic subgroup (RR 3.3 [1.27 - 8.70] and 5.4 [1.44 - 20.0]). In contrast neither the traditional cardiovascular risk factors nor the data of diabetic metabolic control were able to improve prediction. CRP was correlated positively with plasma levels of triglycerides (r = 0.19, p = 0.002), C-peptide (r = 0.21, p = 0.004), postprandial glucose (r = 0.17, p = 0.009), albuminuria (r = 0.16, p = 0.020), and inversely with HDL cholesterol (r = - 0.20, p = 0.002) in type 2 diabetic patients. Conclusions: CRP seems to be a better predictor of death and cardiovascular events than traditional risk factors or parameters of metabolic control in type 2 diabetic patients at high risk for cardiovascular endpoints. Additionally, CRP is associated with several facets of the metabolic syndrome.

Key words

C-reactive protein - mortality - cardiovascular death - metabolic syndrome - type 2 diabetes

References

• 1 Barzilay J I, Abraham L, Heckbert S R, Cushman M, Kuller L H, Resnick H E, Tracy R P. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study.  Diabetes. 2001;  50 2384-2389
• 2 Blackburn H, Keys A, Simonson E, Rautaharju P, Punsar S. The electrocardiogram in population studies.  Circulation. 1960;  21 1160-1175
• 3 Chew D P, Bhatt D L, Robbins M A, Penn M S, Schneider J P, Lauer M S, Topol E J, Ellis S G. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention.  Circulation. 2001;  104 992-997
• 4 Cockcroft D W, Gault M H. Prediction of creatinine clearance from serum creatinine.  Nephron. 1976;  16 31-41
• 5 Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Gallimore J R, Pepys M B. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses.  BMJ. 2000;  321 199-204
• 6 Devaraj S, Xu D Y, Jialal I. C-reactive protein increases plaminogen activator inhibitor-1 expression and activity in human aortic endothelial cells. Implications for the metabolic syndrome and atherothrombosis.  Circulation. 2003;  107 398-404
• 7 di Napoli M, Papa F, Bocola V. C-reactive protein in ischemic stroke: an independent prognostic factor.  Stroke. 2001;  32 917-924
• 8 Dinneen S F, Gerstein H C. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus: a systemic overview of the literature.  Arch Intern Med. 1997;  157 1413-1418
• 9 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults . Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).  J Am Med Assoc. 2001;  285 2486-2497
• 10 Festa A, D'Agostino R, Howard G, Mykkänen L, Tracy R P, Haffner S M. Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: the Insulin Resistance Atherosclerosis Study.  Kidney International. 2000 a;  58 1703-1710
• 11 Festa A, D'Agostino R, Howard G, Mykkänen L, Tracy R P, Haffner S M. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS).  Circulation. 2000 b;  102 42-47
• 12 Festa A, D'Agostino R, Tracy R P, Haffner S M. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes mellitus: the Insulin Resistance Atherosclerosis Study (IRAS).  Diabetes. 2002;  51 1131-1137
• 13 Ford E S. Body mass index, diabetes, and C-reactive protein among U.S. adults.  Diabetes Care. 1999;  22 1971-1977
• 14 Freeman D J, Norrie J, Caslake M J, Gaw A, Ford I, Lowe G DO, O'Reilly D SJ, Packard C J, Sattar N. for the West of Scotland Coronary Prevention Study Group . C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study.  Diabetes. 2002;  51 1596-1600
• 15 Han T S, Sattar N, Williams K, Gonzalez-Villalpando C, Lean M EJ, Haffner S M. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic snydrome in the Mexico City Diabetes Study.  Diab Care. 2002;  25 2016-2021
• 16 Hashimoto H, Kitagawa K, Hougaku H, Shimizu Y, Sakaguchi M, Nagai Y, Iyama S, Yamanishi H, Matsumoto M, Masatsugu H. C-reactive protein is an independent predictor of the rate of increase in early carotid atherosclerosis.  Circulation. 2001;  104 63-67
• 17 Haverkate F, Thompson S G, Pyke S D, Gallimore J F, Pepys M B. Production of C-reactive protein and risk of coronary events in stable and unstable angina: European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group.  Lancet. 1997;  349 462-466
• 18 Jager A, van Hinsbergh V W, Kostense P J, Emeis J J, Yudkin J S, Nijpels G, Dekker J M, Heine R J, Bouter L M, Stehouwer C DA. von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn study.  Arterioscler Thromb Vasc Biol. 1999;  19 3071-3078
• 19 King D A, Mainous A G, Buchanan T A, Pearson W S. C-reactive protein and glycemic control in adults with diabetes.  Diabetes Care. 2003;  26 1535-1539
• 20 Kuller L H, Tracy R P, Shaten J, Meilahn E N. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study: Multiple Risk Factor Intervention Trial.  Am J Epidemiol. 1996;  144 537-547
• 21 McMillan D E. Increased levels of acute-phase serum proteins in diabetes.  Metabolism. 1989;  38 1042-1046
• 22 Messerli A W, Seshadri N, Pearce G L, Sachar R, Hoogwerf B J, Specher D L. Relation of albumin/creatinine ratio to C-reactive protein and to the metabolic syndrome.  Am J Cardiol. 2003;  92 610-612
• 23 Milazzo D, Biasucci L M, Luciani N, Martinelli L, Canosa C, Schiavello R, Maseri A, Possati G. Elevated levels of C-reactive protein before coronary artery bypass grafting predict recurrence of ischemic events.  Am J Cardiol. 1999;  84 459-461 A9
• 24 Ockene I S, Matthews C D, Rifai N, Ridker P M, Reed G, Stanek E. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurement in healthy adults.  Clin Chem. 2001;  47 444-450
• 25 Pearson T A, Mensah G A, Alexander R W, Anderson J L, Cannon R O, Criqui M, Fadl Y Y, Fortmann S P, Hong Y, Myers G L, Rifai N, Smith S C, Taubert K, Tracy R P, Vinicor F. Markers of inflammation and cardiovascular disease. Application to clinical and public health practise. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association.  Circulation. 2003;  107 499-511
• 26 Pickup J C, Mattock M B, Chusney G D, Burt D. NIDDM as a desease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X.  Diabetologia. 1997;  40 1286-1292
• 27 Pradhan A D, Manson J E, Rifai N, Buring J E, Ridker P M. C-reactive protein, interleukin 6, and the risk of developing type 2 diabetes mellitus.  J Am Med Assoc. 2001;  286 327-334
• 28 Ridker P M, Buring J E, Cook N R, Rifai N. C-reactive protein, the metabolic syndrome, and the risk of incident cardiovascular events. An 8-year follow-up of 14 719 initially healthy American women.  Circulation. 2003;  107 391-397
• 29 Ridker P M, Cushman M, Stampfer M J, Tracy R P, Hennekens C H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.  N Engl J Med. 1997;  336 973-979
• 30 Ridker P M, Cushman M, Stampfer M J, Tracy R P, Hennekens C H. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease.  Circulation. 1998;  97 425-428
• 31 Ridker P M, Hennekens C H, Buring J E, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.  N Engl J Med. 2000;  342 836-843
• 32 Ridker P M, Rifai N, Pfeffer M A, Sacks F M, Moye L A, Goldman S, Flaker G C, Braunwald E. for the Cholesterol and Recurrent Events (CARE) Investigators . Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with avarage cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.  Circulation. 1998 b;  98 839-844
• 33 Ridker P M. High-sensitivity C-reactive protein. Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease.  Circulation. 2001;  103 1813-1818
• 34 Ross R. Atherosclerosis: an inflammatory disease.  N Engl J Med. 1999;  340 115-126
• 35 Rossi E, Biasucci L M, Citterio F, Pelliccioni S, Monaco C, Ginnetti F, Agiolillo D J, Grieco G, Luizzo G, Maseri A. Risk of myocardial infarction and angina in patients with severe peripheral vascular disease: predictive role of C-reactive protein.  Circulation. 2002;  105 800-803
• 36 Stehouwer C DA, Gall M A, Twisk J WR, Knudsen E, Emeis J J, Parving H H. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes. Progressive, interrelated, and independently associated with risk of death.  Diabetes. 2002;  51 1157-1165
• 37 Wang C H, Li S H, Weisel R D, Fedak P WM, Dumont A S, Szmitko P, Li R K, Mickle D AG, Verma S. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle.  Circulation. 2003;  107 1783-1790
• 38 Yeh E TH, Willerson J T. Coming of age of C-reactive protein. Using inflammatory markers in cardiology.  Circulation. 2003;  107 370-372
• 39 Yudkin J S, Stehouwer C DA, Emeis J J, Coppack S W. C-Reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction. A potential role for cytokines originating from adipose tissue?.  Arterioscler Thromb Vasc Biol. 1999;  19 972-978
• 40 Yudkin J S, Forrest R D, Jackson C A. Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey.  Lancet. 1988;  2 530-533